Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
Sign in with Google. Opens in new tab
ENTITY
SMARTSCORE: 3.6/5
Antengene (6996 HK)
Watchlist
44
Analysis
Health Care
•
China
Antengene Corporation Limited operates as a specialty pharmaceutical company. The Company produces innovative drugs, selinexor, eltanexor, verdinexor, and other products. Antengene provides its services throughout China.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Antengene
•
05 Nov 2020 23:40
Antengene: Gunning To Move Up in Line
This Insight provides an in-depth review of pre-revenue biotechnology Antegene that plans to list on the HKEX. We discuss the pipeline, market...
Kemp Dolliver, CFA
539 Views
Share
bullish
•
Antengene
•
04 Nov 2020 05:59
Antengene (德琪医药) Pre-IPO: Thoughts on Valuation
Antengene is a biotech company with a focus on in-licensed innovative oncology drugs. The company was founded by Dr Jay Mei, an ex-Celgene...
Ke Yan, CFA, FRM
Follow
442 Views
Share
bullish
•
Antengene
•
03 Nov 2020 09:43
Antengene IPO Initiation: Hunting for a Cure
Leveraging the management team’s expertise, Antegene focuses on the haematology and oncology therapeutic areas. Overall, we believe that Antegene’s...
Arun George
Follow
370 Views
Share
bullish
•
Ant Group
•
01 Nov 2020 03:23
ECM Weekly (1 November 2020) - Ant Group, Sunac Services, New Oriental HK, Bio-Thera
This week, much of the focus is on Ant whereas HK had a disappoint start with the poor debut of KWG Living and Shimao Services. On the other hand,...
Zhen Zhou, Toh
477 Views
Share
bullish
•
Ant Group
•
25 Oct 2020 03:14
ECM Weekly (25 October 2020) - Ant Group, Lufax, JW Thera, Shimao Svcs, GDS Secondary, Nanofilm
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. This week...
Zhen Zhou, Toh
566 Views
Share
First
Previous
5
6
7
8
9
Next
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.53.10
x